These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24660660)

  • 1. A patent review on the development of human cytochrome P450 inhibitors.
    Francis S; Delgoda R
    Expert Opin Ther Pat; 2014 Jun; 24(6):699-717. PubMed ID: 24660660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based ligand design to overcome CYP inhibition in drug discovery projects.
    Brändén G; Sjögren T; Schnecke V; Xue Y
    Drug Discov Today; 2014 Jul; 19(7):905-11. PubMed ID: 24642031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them.
    Guo Z; Johnson V; Barrera J; Porras M; Hinojosa D; Hernández I; McGarrah P; Potter DA
    Cancer Metastasis Rev; 2018 Sep; 37(2-3):409-423. PubMed ID: 30066055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids.
    Salminen KA; Meyer A; Jerabkova L; Korhonen LE; Rahnasto M; Juvonen RO; Imming P; Raunio H
    Phytomedicine; 2011 Apr; 18(6):533-8. PubMed ID: 20851588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
    Ren S; Zeng J; Mei Y; Zhang JZ; Yan SF; Fei J; Chen L
    Drug Metab Dispos; 2013 Jan; 41(1):60-71. PubMed ID: 23033255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cytochrome P450 inhibitors on peroxidase activity.
    Martinkova M; Kubickova B; Stiborova M
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():33-40. PubMed ID: 23353841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of cardiac cytochrome P450 in patients with heart failure.
    Aspromonte N; Monitillo F; Puzzovivo A; Valle R; Caldarola P; Iacoviello M
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):327-39. PubMed ID: 24387291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Inorganic Systems and Photoactive Metal Compounds on Cytochrome P450 Enzymes and Metabolism: From Induction to Inhibition.
    Havrylyuk D; Heidary DK; Glazer EC
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability.
    Ong CE; Pan Y; Mak JW; Ismail R
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1097-113. PubMed ID: 23682848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics.
    Martinez MN; Antonovic L; Court M; Dacasto M; Fink-Gremmels J; Kukanich B; Locuson C; Mealey K; Myers MJ; Trepanier L
    Drug Metab Rev; 2013 May; 45(2):218-30. PubMed ID: 23432217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).
    Dolušić E; Frédérick R
    Expert Opin Ther Pat; 2013 Oct; 23(10):1367-81. PubMed ID: 23992582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition.
    Zheng YF; Bae SH; Choi EJ; Park JB; Kim SO; Jang MJ; Park GH; Shin WG; Oh E; Bae SK
    Food Chem Toxicol; 2014 Jun; 68():117-27. PubMed ID: 24632066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450s in the development of target-based anticancer drugs.
    Purnapatre K; Khattar SK; Saini KS
    Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating cytochrome P450 3A4 genotype expression and FT-IR/Raman spectroscopy data as means of identification of breast tumors.
    Miller SO; Ewing GP; Howard C; Tachikawa H; Bigler SA; Barber WH; Angel M; McDaniel DO
    Biomed Sci Instrum; 2003; 39():24-9. PubMed ID: 12724863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications.
    Zhang YY; Yang L
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):621-9. PubMed ID: 19473111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature.
    Lavecchia A; Di Giovanni C; Cerchia C
    Expert Opin Ther Pat; 2014 Apr; 24(4):383-400. PubMed ID: 24432979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
    Kontijevskis A; Komorowski J; Wikberg JE
    J Chem Inf Model; 2008 Sep; 48(9):1840-50. PubMed ID: 18693719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streptomyces cytochromes P450: applications in drug metabolism.
    Lamb DC; Waterman MR; Zhao B
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1279-94. PubMed ID: 23738914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.